These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 37643815)

  • 1. Initial dosage optimisation of cyclosporine in Chinese paediatric patients undergoing allogeneic haematopoietic stem cell transplantation based on population pharmacokinetics: a retrospective study.
    Feng H; Wang X; Zheng W; Liu S; Jiang H; Lin Y; Qiu H; Chan TF; Huang M; Li Y; Mo X; Li J
    BMJ Paediatr Open; 2023 Aug; 7(1):. PubMed ID: 37643815
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Population pharmacokinetics of ciclosporin in haematopoietic allogeneic stem cell transplantation with emphasis on limited sampling strategy.
    Wilhelm AJ; de Graaf P; Veldkamp AI; Janssen JJ; Huijgens PC; Swart EL
    Br J Clin Pharmacol; 2012 Apr; 73(4):553-63. PubMed ID: 21988410
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Population pharmacokinetics of cyclosporine in Chinese children receiving hematopoietic stem cell transplantation.
    Li TF; Hu L; Ma XL; Huang L; Liu XM; Luo XX; Feng WY; Wu CF
    Acta Pharmacol Sin; 2019 Dec; 40(12):1603-1610. PubMed ID: 31341257
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Population pharmacokinetics of ciclosporin in allogeneic hematopoietic stem cell transplant recipients: C-reactive protein as a novel covariate for clearance.
    Ling J; Yang XP; Dong LL; Jiang Y; Zou SL; Hu N; Chen R
    J Clin Pharm Ther; 2022 Apr; 47(4):483-492. PubMed ID: 34779003
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Population pharmacokinetics and individualized dosage prediction of cyclosporine in allogeneic hematopoietic stem cell transplant patients.
    Xue L; Zhang WW; Ding XL; Zhang JJ; Bao JA; Miao LY
    Am J Med Sci; 2014 Dec; 348(6):448-54. PubMed ID: 25247760
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Posttransplant day significantly influences pharmacokinetics of cyclosporine after hematopoietic stem cell transplantation.
    Jacobson PA; Ng J; Green KG; Rogosheske J; Brundage R
    Biol Blood Marrow Transplant; 2003 May; 9(5):304-11. PubMed ID: 12766880
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Population pharmacokinetics of cyclosporine A based on NONMEM in Chinese allogeneic hematopoietic stem cell transplantation recipients.
    Zhou H; Gao Y; Cheng XL; Li ZD
    Eur J Drug Metab Pharmacokinet; 2012 Dec; 37(4):271-8. PubMed ID: 22446981
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Population pharmacokinetics of cyclosporine in hematopoietic stem cell transplant patients: consideration of genetic polymorphisms.
    Kim MG; Kim IW; Choi B; Han N; Yun HY; Park S; Oh JM
    Ann Pharmacother; 2015 Jun; 49(6):622-30. PubMed ID: 25818517
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of a Bayesian Individualization of Cyclosporine Dosage Regimen for Children Undergoing Allogeneic Hematopoietic Cell Transplantation: A Cost-Effectiveness Analysis.
    Beyron C; Ceraulo A; Bertrand Y; Bleyzac N; Philippe M
    Ther Drug Monit; 2021 Aug; 43(4):481-489. PubMed ID: 33814541
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Population pharmacokinetic study of cyclosporine in the hematopoietic stem cell transplant recipients.
    Zhou Y; Sheng XY; Xu JY; Bi SS; Lu W; Cui YM
    Int J Clin Pharmacol Ther; 2013 Jul; 51(7):568-75. PubMed ID: 23611568
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cyclosporine levels > 195 μg/L on day 10 post-transplant was associated with significantly reduced acute graft-versus-host disease following allogeneic hematopoietic stem cell transplantation.
    Bianchi M; Heim D; Lengerke C; Halter J; Gerull S; Kleber M; Tsakiris DA; Passweg J; Tzankov A; Medinger M
    Ann Hematol; 2019 Apr; 98(4):971-977. PubMed ID: 30542943
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Optimizing cyclosporine A dose post allogeneic hematopoietic stem cell transplantation in paediatric cancer patients.
    Elnaggar M; Hafez H; Abdallah A; Hamza M; Khalaf MM; El-Haddad A
    J Oncol Pharm Pract; 2024 Sep; 30(6):983-991. PubMed ID: 37528663
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Population pharmacokinetics of cyclosporine A in pediatric patients with thalassemia undergoing allogeneic hematopoietic stem cell transplantation.
    Cai R; Zhang L; Wu T; Huang Y; Lu J; Huang T; Wu Y; Wu D; Qi J; Niu L; Xiao Y; Chen X; Liu Y; Luo Y; Liu T
    Eur J Clin Pharmacol; 2024 May; 80(5):685-696. PubMed ID: 38329479
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reaching the cyclosporine a level target slowly in four weeks correlates with better prognosis for Chinese patients after allogeneic haematopoietic cell transplantation.
    Fan Q; Hui X; Li X; Li Q; Yang D; Wang Y
    Hematology; 2023 Dec; 28(1):2275893. PubMed ID: 37975575
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of cyclosporine-A concentration in T-cell replete haploidentical allogeneic stem cell transplantation.
    Yang X; Yang S; Sun A; Qiu H; Tang X; Han Y; Wu D
    Clin Transplant; 2018 Apr; 32(4):e13220. PubMed ID: 29493007
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A model based on machine learning for the prediction of cyclosporin A trough concentration in Chinese allo-HSCT patients.
    Song L; Huang CR; Pan SZ; Zhu JG; Cheng ZQ; Yu X; Xue L; Xia F; Zhang JY; Wu DP; Miao LY
    Expert Rev Clin Pharmacol; 2023 Jan; 16(1):83-91. PubMed ID: 36373407
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Premature cyclosporine cessation and TBI-containing conditioning regimen increase the risk of acute GvHD in children undergoing unrelated donor hematopoietic stem cell transplantation.
    Szmit Z; Kałwak K; Król A; Mielcarek-Siedziuk M; Salamonowicz M; Frączkiewicz J; Ussowicz M; Owoc-Lempach J; Gorczyńska E
    Adv Clin Exp Med; 2019 Sep; 28(9):1185-1192. PubMed ID: 31430073
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Achievement of target cyclosporine concentrations as a predictor of severe acute graft versus host disease in children undergoing hematopoietic stem cell transplantation and receiving cyclosporine and methotrexate prophylaxis.
    Punnett A; Sung L; Price V; Das P; Diezi M; Doyle J; Dupuis LL
    Ther Drug Monit; 2007 Dec; 29(6):750-7. PubMed ID: 18043472
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Occurrence and influencing factors of cyclosporine A on the kidney injury following allogeneic hematopoietic stem cell transplantation: A systematic review and meta-analysis.
    Lu R; Shi Y; Yang M; Yang N; He S; Xin L; Qin Y; Li H; Zeng L; Zou K; Yang C; Huang L; Shi W; Qiu X; Lu X; Zhang L
    Int Immunopharmacol; 2023 Sep; 122():110633. PubMed ID: 37451015
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.